Prothena Corporation plc (PRTA)
| Market Cap | 619.08M |
| Revenue (ttm) | 9.68M |
| Net Income (ttm) | -244.09M |
| Shares Out | 53.83M |
| EPS (ttm) | -4.53 |
| PE Ratio | n/a |
| Forward PE | 46.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 383,583 |
| Open | 10.84 |
| Previous Close | 10.79 |
| Day's Range | 10.83 - 11.57 |
| 52-Week Range | 4.32 - 11.69 |
| Beta | -0.33 |
| Analysts | Buy |
| Price Target | 19.00 (+65.22%) |
| Earnings Date | May 7, 2026 |
About PRTA
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau a... [Read more]
Financial Performance
In 2025, Prothena Corporation's revenue was $9.68 million, a decrease of -92.83% compared to the previous year's $135.16 million. Losses were -$244.09 million, 99.6% more than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for PRTA stock is "Buy." The 12-month stock price target is $19.0, which is an increase of 65.22% from the latest price.
News
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announces Novo Nordisk obtains Fast Track Designation from the U.S. FDA for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy.
Prothena Announces Leadership Team Updates
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena promoting Ms. Kingston to Chief Strategy Officer and Mr. Isaacs to General Counsel and Corporate Secretary. Mr. Malecek is departing in June.
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena partners presented clinical data updates for prasinezumab for Parkinson's and BMS-986446 for Alzheimer's disease at AD/PD™ 2026.
Prothena Corporation Transcript: The Citizens Life Sciences Conference 2026
The company highlighted its robust partnered and proprietary pipeline, with major phase III programs in Parkinson’s and ATTR cardiomyopathy, and significant financial milestones expected this year. Strategic capital allocation and the advancement of the CYTOPE platform for undruggable targets were emphasized.
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena earned a $50 million milestone from Novo Nordisk related to enrollment in the Phase 3 CLEOPATTRA trial evaluating coramitug for ATTR-CM.
Prothena Announces up to $100 Million Share Repurchase Plan
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced its Board has authorized a Share Repurchase Plan so it may repurchase up to $100 million of the Company's outstanding shares.
Prothena Corporation Earnings Call Transcript: Q4 2025
Advanced key partnered programs into phase 3, introduced CYTOPE technology, and maintained a strong cash position. 2025 financials were favorable to guidance, with 2026 outlook projecting lower cash use and potential $105M in milestones.
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights.
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that it will report its fourth quarter and full year 2025 financial results on Thursday 2/19/26 with a conference call at 4:30pm ET.
Prothena Announces Board of Directors Update
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein...
Prothena Corporation Transcript: Evercore ISI 8th Annual HealthCONx Conference
Multiple late-stage neurology programs are advancing, with phase III trials for Parkinson's and ATTR cardiomyopathy, and key Alzheimer's studies in progress. Transferrin technology may enhance CNS drug delivery, and partnerships are central to strategy. Key data and milestones are expected through 2027.
Prothena Corporation Transcript: Piper Sandler 37th Annual Healthcare Conference
Multiple late-stage partnered programs are advancing, with key milestones and data expected through 2026. Significant financial upside remains from milestone payments and royalties, while new technology and business development initiatives are set to drive further value.
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025.
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Phase 2 clinical data for coramitug, a potential first-in-class amyloid depleter antibody, for the treatment of ATTR-CM published in Circulation.
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the third quarter and first nine months of 2025 and provided business highlights.
Prothena to Report Third Quarter 2025 Financial Results on November 6
DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena will report its third quarter 2025 financial results on Thursday November 6, 2025, after the close of the U.S. financial markets.
Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--PRTA announced that BMS communicated that the FDA granted Fast Track Designation to BMS-986446, an anti-tau antibody in P2 for Alzheimer's disease.
Prothena Corporation Transcript: Cantor Global Healthcare Conference 2025
Restructuring has streamlined operations to focus on key partnered programs, with major milestones expected in 2026 from phase 3 advancements in Parkinson’s and ATTR cardiomyopathy. Financial strategy emphasizes shareholder value through potential share repurchases and milestone-driven partnerships.
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein...
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program.
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the second quarter and first six months of 2025 and provided business highlights.
Prothena to Report Second Quarter 2025 Financial Results on August 4
DUBLIN--(BUSINESS WIRE)--Prothena today announced that it will report its second quarter and first six months of 2025 financial results on August 4, 2025.
Prothena Announces Corporate Restructuring
DUBLIN--(BUSINESS WIRE)--Prothena announced that the Company has initiated an approximate 63% reduction in its workforce.
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson's disease.